Manufacturing supervision of our products

During the year 2016 we made quality agreements with sub-contracted manufacturers, who have several certificates issued by COFEPRIS which endorse the manufacturing of our OTC medicines and cosmetic products. Additionally, at Genomma Lab Internacional we have a strategy to 2020 in which we intend to raise our quality standards throughout the following cycles.

Cycle 2016


Quality is controlled in laboratories for manufacturers.

Key procedures are defined.

Start of work with quality dashboard.

Implementation of exchange controls.

Cycle 2017

Expansion of process improvement

Quality is controlled.

Audit group certification on management systems.

Development of improvement projects accomplished by implants on the floor.

Signed physical standards are defined for all launches.

Delivery, purchase and development manuals are set.

Cycle 2018

Quality forwards: by measuring the customer

Metrics for customer satisfaction and product repurchase are initiated.

Consolidation of specifications’ definition for raw and packaging materials of the most important products.

Conclusion of the suppliers’ certification process.

Continuous improvement essentially comes into development.

Cycle 2019

Quality backwards: improvement in raw materials

Consolidation of specifications’ definition for raw and packaging materials of the most important products.

Improvement projects are focused on the raw material suppliers.

Start of the certification of raw materials’ suppliers.

The implants act mainly with suppliers.

Cycle 2020

Quality as strategy

Quality as the protagonist to achieve stable product and at lower cost.

The quality know-how is used to have product in the market in less time and with stable processes.

Quality is controlled from the supplier to the customer.

*Chart shared by the Quality area

The great challenge that we determine for 2017 is to achieve the processes standardization at international level, as well as to engage our value chain at global level to adhere to the good labor practices, to our own quality standards and to those of our regulators.

Pharmaceutical and Cosmetic Clinical Research

In order to measure and monitor the quality of our pharmaceutical products, we have two very important programs:

  • PHARMACOVIGILANCE: monitoring of possible adverse reactions that any of our medicine consumers might present.
  • TECHNOVIGILANCE: monitoring of medical devices to determine if they comply with the required safety measures.

In relation to cosmetic products we have promoted the program COSMETOVIGILANCE, through which we perform analysis of adverse reactions. Although the program is not legally required by any official body, our commitment as a Socially Responsible Company (ESR, for its acronym in Spanish) leads us to include it as part of our continuous improvement processes.

During 2016, studies of efficacy and cosmetic and pharmaceutical safety were carried out at Genomma Lab Internacional. All the studies we carry out are based on international methodologies such as The European Cosmetic and Perfumery Association (COLIPA) [1] and the National Agency for Health Surveillance (ANVISA).

The cosmetic-efficacy studies that we perform to our products are always carried out by a third party in order to keep objectivity with regard to the results of these tests. Likewise, we carry out safety studies on all our cosmetic products and our directives in each case prohibit the use of animals in any of the studies that are carried out.

The innovation, quality and efficiency in our operations allow us to focus on implementing and monitoring processes to prevent loss or waste, creating value with high productivity, safety, costs and ethics, aimed at the continuous improvement of customer and consumer service.


Reporte de Sustentabilidad 2016 de Genomma Lab Internacional